Serina Therapeutics Begins First-in-Patient Dosing in Phase 1b Trial of SER‑252 for Advanced Parkinson’s Disease
- March 10, 2026
New Gene Editing Program Aims to Address Root Cause of PKU
From Psychiatric Bind to Clinical Solution: The VMAT2 Revolution in Treating Tardive Dyskinesia
Brain Cancers: FDA Approves Pembrolizumab Combo
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Spinal muscular atrophy (SMA) is a condition that many people may not hear about often, but for those living with it, it’s part of daily life. Raising awareness helps create understanding — not just about the condition itself, but about the strength, resilience, and challenges that come with it.
Learning about SMA helps us build a more informed and compassionate community where people affected by rare diseases feel seen, supported, and understood. Every conversation, every shared fact, and every moment of awareness helps bring more visibility to a condition that deserves it.
#SpinalMuscularAtrophy #SMA #RareDiseaseOfTheWeek #RareDisease #RareDiseaseAwareness #PatientWorthy
New research may offer hope for people living with #pku.
While still in development, this approach reflects growing momentum toward potentially durable, one-time genetic treatments for rare diseases.
patientworthy.com/2026/03/10/new-gene-editing-program-aims-to-address-root-cause-of-pku/
What is tardive dyskinesia? Keep reading to learn what this movement disorder is and what you need to know. Share your TD journey with us here: bit.ly/4dV7gru
#tardivedyskinesia #TDawareness #mentalhealthmatters #PatientWorthy
